Evidence map›Paper›PMID 39709673›Full record

ArticleInternational journal of surgery case reports2025

Histopathological analysis of gamma sarcoglycanopathy in Moroccan patients: A case series.

Hafsa E L Ouazzani, Fouad Zouaidia, Nadia Cherradi, Mahdi Karkouri

Abstract read
In one paragraph

Article in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hafsa E L OuazzaniDepartment of Pathology HSR, Ibn Sina University Hospital Center, Rabat, Morocco; Mohammed V University in Rabat, Morocco. Electronic address: Hafsaelouazzani2023@gmail.com.
Fouad ZouaidiaDepartment of Pathology Ibn Sina, Ibn Sina University Hospital Center, Rabat, Morocco; Mohammed V University in Rabat, Morocco.
Nadia CherradiDepartment of Pathology HSR, Ibn Sina University Hospital Center, Rabat, Morocco; Mohammed V University in Rabat, Morocco.
Mahdi KarkouriDepartment of Pathology of Ibn Roched University Hospital Center, Casablanca, Morocco; Hassan II University in Casablanca, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and importanceIn Morocco, diagnosing Gamma Sarcoglycanopathies mainly relies on histopathological analysis of muscle biopsies due to limited genetic and molecular research access. This study highlights the significance of muscle biopsies and explores potential predictive factors and possible correlation between histopathological abnormalities and clinical phenotypes. CASE PRESENTATION: Muscle biopsies of six patients diagnosed with γ-sarcoglycanopathy were collected over two years. Pathological analysis was initially performed on slides stained with Hematoxylin-Eosin and Gomori Trichrome. Additionally, cryosections marked for dystrophin, alpha, beta, and gamma sarcoglycans were reviewed. In the second phase of the analysis, formalin-fixed sections from each biopsy were immunostained for various markers: "anti-CD68" for macrophagic cells, "anti-CD56" for satellite cells, and "anti-CD31" for vascular capillary. These stained sections were then carefully examined. CLINICAL DISCUSSION: The clinical presentation of the disease was uniform and consistent with Duchenne-like dystrophy. However, the histological abnormalities were heterogeneous and did not correlate with the severity of the clinical phenotype. The Loss of expression of a Sarcoglycan and earlier age of onset appear to be the most significant predictive markers of disease progression. Immuno-staining patterns for CD68, CD56, and CD31 indicated an impairment in the muscle regeneration process, probably, at an early stage of the disease.

conclusionThis study's findings are crucial for understanding pathogenesis and identifying new therapeutic targets. However, because of the small sample size, further confirmation through a larger cohort is necessary.

Indexed as

HistologyImmunohistochemistryMuscle biopsySarcoglycanopathy

Identifiers

PMID39709673
PMCPMC11726778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.